[to top of second column]
Earlier this year, Gilead received FDA approval to market Truvada as the first preventive medicine for healthy people who are at high risk of acquiring HIV. Truvada was first approved in 2004 for patients already infected with the virus.
Gilead Sciences Inc. is based in Foster City, Calif. Shares of the company fell 10 cents to close at $57.19 and then added 11 cents in after-hours trading.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor